Relmada Therapeutics Inc.

RLMD | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.20

+$0.04 (+0.96%)

Sep 22, 2026, 12:21 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Income Statement Balance Sheet Cashflow Statement Ratios

Annual Quarterly TTM

Fiscal Quarter Period Ending	Q2 2026 Jun 29, 2026	Q1 2026 Mar 30, 2026	Q4 2025 Dec 30, 2025	Q3 2025 Sep 29, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024 Dec 30, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 29, 2024	Q1 2024 Mar 30, 2024	Q4 2023 Dec 30, 2023	Q3 2023 Sep 29, 2023	Q2 2023 Jun 29, 2023	Q1 2023 Mar 30, 2023	Q4 2022 Dec 30, 2022	Q3 2022 Sep 29, 2022	Q2 2022 Jun 29, 2022	Q1 2022 Mar 30, 2022	Q4 2021 Dec 30, 2021	Q3 2021 Sep 29, 2021	Q2 2021 Jun 29, 2021	Q1 2021 Mar 30, 2021
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-15.01M	-19.46M	-20.33M	-10.33M	-10.22M	-18.22M	-19.08M	-23.01M	-18.82M	-22.99M	-26.83M	-22.69M	-26.03M	-28.15M	-38.7M	-38.74M	-45.51M	-38.3M	-34.18M	-42.65M	-26.46M	-22.41M
Interest Income	2.3M	959.76K	387.23K	247.01K	321.46K	440.29K	654.64K	856.48K	963.01K	1.06M	1.26M	1.32M	1.36M	1.21M	1.12M	827.61K	387.33K	329.95K	158.65K	297.65K	322.81K	419.97K
Pretax Income	-12.91M	-19.05M	-19.87M	-10.09M	-9.87M	-17.56M	-18.66M	-21.73M	-17.77M	-21.83M	-25.17M	-22M	-25.3M	-26.32M	-37.94M	-39.42M	-39.94M	-39.75M	-34.38M	-42.61M	-26.55M	-22.22M
Net Income	-12.91M	-19.05M	-19.87M	-10.09M	-9.87M	-17.56M	-18.66M	-21.73M	-17.77M	-21.83M	-25.17M	-22M	-25.3M	-26.32M	-37.94M	-39.42M	-39.94M	-39.75M	-34.38M	-42.61M	-26.55M	-22.22M
Selling & General & Admin	6.62M	11.37M	12.26M	6.29M	7.4M	6.27M	8.08M	11.86M	8.1M	9.68M	12.08M	12.24M	12.29M	12.29M	11.83M	8.21M	14.6M	13.28M	8.91M	8.66M	9.13M	8.38M
Research & Development	8.39M	8.09M	8.07M	4.04M	2.82M	11.95M	11M	11.15M	10.72M	13.31M	14.75M	10.45M	13.74M	15.86M	26.87M	30.53M	30.91M	25.01M	25.27M	33.99M	17.33M	14.02M
Other Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0	n/a	n/a	0	0	n/a	n/a	n/a
Operating Expenses	15.01M	19.46M	20.33M	10.33M	10.22M	18.22M	19.08M	23.01M	18.82M	22.99M	26.83M	22.69M	26.03M	28.15M	38.7M	38.74M	45.51M	38.3M	34.18M	42.65M	26.46M	22.41M
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	15.01M	19.46M	20.33M	10.33M	10.22M	18.22M	19.08M	23.01M	18.82M	22.99M	26.83M	22.69M	26.03M	28.15M	38.7M	38.74M	45.51M	38.3M	34.18M	42.65M	26.46M	22.41M
Income Tax Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	112.38M	86.6M	68.26M	33.19M	33.19M	30.41M	30.17M	30.17M	30.17M	30.13M	30.1M	30.1M	30.1M	30.1M	30.1M	30.06M	29.94M	28.39M	19.08M	17.48M	17.06M	16.57M
Shares Outstanding (Diluted)	112.38M	86.6M	68.26M	33.19M	33.19M	30.41M	30.17M	30.17M	30.17M	30.13M	30.1M	30.1M	30.1M	30.1M	30.1M	30.06M	29.94M	28.39M	19.08M	17.48M	17.06M	16.57M
EPS (Basic)	-0.11	-0.22	-0.29	-0.30	-0.30	-0.58	-0.62	-0.72	-0.59	-0.72	-0.84	-0.73	-0.84	-0.87	-1.26	-1.31	-1.33	-1.40	-1.80	-2.44	-1.56	-1.34
EPS (Diluted)	-0.11	-0.22	-0.29	-0.30	-0.30	-0.58	-0.62	-0.72	-0.59	-0.72	-0.84	-0.73	-0.84	-0.87	-1.26	-1.31	-1.33	-1.40	-1.80	-2.44	-1.56	-1.34
EBITDA	-12.91M	-19.05M	-19.87M	-10.09M	-9.87M	-17.56M	418.42K	1.28M	1.05M	-21.83M	1.66M	-22M	-25.3M	-26.32M	-37.94M	-39.42M	-39.93M	-39.75M	-34.38M	-42.61M	-26.55M	-22.4M
EBIT	-12.91M	-19.05M	-19.87M	-10.09M	-9.87M	-17.56M	-18.66M	-21.73M	-17.77M	-21.83M	-25.17M	-22M	-25.3M	-26.32M	-37.94M	-39.42M	-39.94M	-39.75M	-34.38M	-42.61M	-26.55M	-22.41M
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	19.08M	23.01M	18.82M	n/a	26.83M	n/a	n/a	n/a	315	315	315	315	n/a	n/a	452	806